Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that it has dosed the first patient in a Phase 1 clinical trial of ABSK131, an investigational and novel PRMT5*MTA inhibitor in patients with advanced or metastatic solid tumors with MTAP deficiency. In March 2025, ABSK131 received IND clearance from the Center for Drug Evaluation of the China National Medical Products Administration. In December 2024, ABSK131 received IND clearance from the U.S. Food and Drug Administration.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK131 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, July 23, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Doses First Patient in Phase 1 Clinical Trial for ABSK131, a Novel PRMT5*MTA Inhibitor

On July 23, 2025, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that it has dosed the first patient in a Phase 1 clinical trial of ABSK131, an investigational and novel PRMT5*MTA inhibitor in patients with advanced or metastatic solid tumors with MTAP deficiency. In March 2025, ABSK131 received IND clearance from the Center for Drug Evaluation ("**CDE**") of the China National Medical Products Administration ("**NMPA**"). In December 2024, ABSK131 received IND clearance from the U.S. Food and Drug Administration ("**FDA**").

The ongoing clinical study is conducted under the title "A Phase 1, First-in-Human, Multicenter, Open-Label Study of ABSK131 to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Patients with Advanced/Metastatic Solid Tumors with MTAP deficiency."

Approximately 15% of solid tumors lack expression of MTAP, a tumor suppressor gene[1]. Solid tumors with high rates of MTAP deficiency include non-small cell lung cancer ("**NSCLC**") (15.7%), pancreatic cancer (21.7%), esophageal cancer (28.4%), mesothelioma (32.2%), and gastrointestinal cancer (10.4% of gastric and 1% of colorectal cancer)[2], of which mesotheliomas and pancreatic cancers have no approved targeted therapies. Recent studies have demonstrated that selectively targeting PRMT5*MTA shows promise as a therapeutic strategy for MTAP-deficient cancers.

About ABSK131

ABSK131 is a novel, small molecule MTA-cooperative PRMT5 inhibitor in development by Abbisko Therapeutics, with strong anti-tumor activity. In preclinical studies, ABSK131 demonstrated excellent selectivity for MTAP-deleted cancer cells, as well as favorable drug metabolism and pharmacokinetic properties for oral dosing.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

References:

1. Kalev P, Hyer ML, Gross S, et al. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage. Cancer Cell. 2021;39(2):209-224. e11. doi:10.1016/j.ccell.2020.12.010

2. Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther. 2011;11(7):627-632. doi:10.4161/cbt.11.7.14948.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.